Connect with us

News

Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

gbafNews28

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 — Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

“We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.”

Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.”

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc. Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For more information, visit https://www.gaintherapeutics.com/.

Forward-Looking Statements Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gain’s product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Gain Therapeutics Investor Contact: Daniel Ferry LifeSci Advisors +1 617-430-7576 [email protected]

Gain Therapeutics Media Contact: Cait Williamson, Ph.D. LifeSci Communications +1 646-751-4366 [email protected]

Primary Logo

News

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

gbafNews28

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Decision Diagnostics Corp. (Decision Diagnostics or the Company) (OTC: DECN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between March 3, 2020 and December 17, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before March 16, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the FDA’s EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Companys public statements were false and materially misleading throughout the class period. When the market learned the truth about Decision Diagnostics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

Continue Reading

News

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds CD Projekt S.A. Investors of Important February 22 Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – OTGLY, OTGLF

gbafNews28

NEW YORK, Jan. 16, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CD Projekt S.A. (OTC: OTGLY, OTGLF) between January 16, 2020 and December 17, 2020, inclusive (the “Class Period”), of the important February 22, 2021 lead plaintiff deadline in the first filed securities class action commenced by the firm. The lawsuit seeks to recover damages for CD Projekt investors under the federal securities laws.

To join the CD Projekt class action, go http://www.rosenlegal.com/cases-register-2010.htmlhttp://www.rosenlegal.com/cases-register-1961.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or PlayStation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the PlayStation store, and Sony, Microsoft and CD Projekt would be forced to offer full refunds for the game; (3) consequently, CD Projekt would suffer reputational and pecuniary harm; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 22, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2010.htmlhttp://www.rosenlegal.com/cases-register-1961.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-globally-recognized-investor-counsel-reminds-cd-projekt-sa-investors-of-important-february-22-deadline-in-securities-class-action-first-filed-by-the-firm-encourages-investors-with-losses-in-excess-of-100k-to-contact-fi-301209606.html

SOURCE Rosen Law Firm, P.A.

Continue Reading

News

ROSEN, A TOP RANKED LAW FIRM, Reminds Sona Nanotech Inc. Investors of Important February 16 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – SNANF

gbafNews28

NEW YORK, Jan. 16, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sona Nanotech Inc. (OTC: SNANF) between July 2, 2020 and November 25, 2020, inclusive (the “Class Period”) of the important February 16, 2021 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Sona investors under the federal securities laws.

To join the Sona class action, go http://www.rosenlegal.com/cases-register-1994.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) it was unreasonable for Sona to represent that it could receive results from field studies of its COVID-19 antigen test within a month;  (2) Sona's positive statements about its COVID-19 antigen test were unfounded as the U.S. Food and Drug Administration (“FDA”) would deprioritize emergency use authorization approval of Sona's antigen test finding it did not meet “the public health need” criterion; (3) it was unreasonable for Sona to believe that data gathered over such a short period of time would be sufficient for approval of its antigen test by either the FDA or Health Canada; (4) Sona would have to withdraw its submission for Interim Order authorization from Health Canada for the marketing of its COVID-19 antigen test as it lacked sufficient clinical data to support approval; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 16, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1994.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-reminds-sona-nanotech-inc-investors-of-important-february-16-deadline-in-first-filed-securities-class-action-commenced-by-the-firm-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm-301209602.html

SOURCE Rosen Law Firm, P.A.

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News1 hour ago

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Decision...

gbafNews28 gbafNews28
News2 hours ago

We need humanitarian access to Tigray as urgent first step towards peace in Ethiopia

BRUSSELS, 15 January 2021 / PRN Africa / — For more than two months, conflict has been raging in the...

gbafNews28 gbafNews28
News2 hours ago

ROSEN, A TOP RANKED LAW FIRM, Reminds Sona Nanotech Inc. Investors of Important February 16 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – SNANF

NEW YORK, Jan. 16, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities...

gbafNews28 gbafNews28
News2 hours ago

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds CD Projekt S.A. Investors of Important February 22 Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – OTGLY, OTGLF

NEW YORK, Jan. 16, 2021 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities...

gbafNews28 gbafNews28
News2 hours ago

CIFI issues US$419 million senior notes at a coupon rate of 4.375% with a 6.25-year maturity

Hit the record for the longest maturity period and the lowest coupon rate of the Group’s offshore bond issuance Optimize the...

gbafNews28 gbafNews28
News2 hours ago

DIT Group grew rapidly in 2020 with 72% increase in sales volume

Speeding Up Business Expansion Nationwide by Signing Several Strategic Cooperation Agreements and Collaborating with CCRE Group   HONG KONG SAR – Media...

gbafNews28 gbafNews28
News2 hours ago

Burkhard Eling takes up role of CEO at Dachser

The next generation has arrived: A new Executive Board team for the new year   KEMPTEN / HONG KONG –...

gbafNews28 gbafNews28
News2 hours ago

Management Development Institute of Singapore (MDIS) facilitates upskilling & reskilling with online MBAs & courses

SINGAPORE – Media OutReach – 5 January 2021 – As we to move into Phase 3 of Covid-19 towards the end...

gbafNews28 gbafNews28
News2 hours ago

Suncity Group Announces 2021 Outlook

Striding Towards a Bright Future   MACAU – Media OutReach – 5 January 2021 – Under the impact of the COVID-19 pandemic, 2020...

gbafNews28 gbafNews28
News2 hours ago

NEFIN in Partnership with Hong Kong Baptist Theological Seminary (HKBTS) Embrace Carbon Neutrality for a Green Campus

316 Solar Panels Built on 6 Rooftops of HKBTS Campus Buildings   HONG KONG SAR – Media OutReach – 5 January 2021 –...